Can platelet-rich plasma (PRP) help vaginal dryness?
Can platelet-rich plasma (PRP) help vaginal dryness? Early studies suggest PRP may improve comfort for some people with genitourinary syndrome of menopause (GSM), but evidence is small and mixed. UK guideline first lines remain moisturisers, suitable lubricants and, when needed, local vaginal oestrogen or DHEA; PRP is a potential add-on after these. Discuss benefits, limits, costs and alternatives before deciding. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
Can platelet-rich plasma (PRP) help vaginal dryness? PRP is made by spinning a small sample of your blood to concentrate platelets and growth factors, then injecting small amounts into target tissues. In the vulvo-vaginal area, the aim is to support repair, blood flow and lubrication—a different mechanism to local vaginal oestrogen or vaginal DHEA, which address the low-oestrogen biology of genitourinary syndrome of menopause (GSM). Small, early studies and case series suggest PRP may ease dryness, dyspareunia (pain with sex), and stinging at the entrance (vestibule) for some. However, trials are limited, often lack long follow-up, and use varied techniques, so results are mixed and not yet as robust as guideline therapies.
Where PRP fits in a UK, step-wise pathway. First build non-hormonal foundations: a scheduled vaginal moisturiser (many prefer hyaluronic acid gels) several times weekly for day-to-day hydration, plus a compatible personal lubricant for higher-friction moments—water-based (versatile, condom-friendly), silicone-based (long-lasting glide if the entrance is tender), or oil-based (rich feel but may degrade latex condoms/toys). If GSM remains intrusive, add local vaginal oestrogen (cream, tablet/pessary, ring) or consider vaginal DHEA after assessment. PRP is generally discussed after these steps, or when hormones are unsuitable/declined and symptoms persist despite diligent basics.
What to expect if you proceed. A typical session involves a blood draw, centrifugation, then small injections to the vestibule and/or vaginal wall. Numbing is used; most describe pressure, scratch or brief sting. You may notice transient spotting or soreness for 24–72 hours. Reported improvements—when they occur—tend to be gradual over weeks: easier glide at initial penetration, fewer micro-tears at the posterior fourchette, calmer day-to-day “sandpaper” feel on walks or cycling. Because GSM has an ongoing hormonal driver, benefits (if any) may soften over months; some people schedule a review around 3–6 months to decide on further care.
Safety and regulation points. PRP uses your own blood (autologous), so allergic reactions are uncommon, but injection-site tenderness, bruising, spotting and temporary irritation can occur. As with any intimate-area procedure, strict sterile technique matters. PRP kits and devices used to prepare injections should meet UK standards for medical devices and be used by trained clinicians with clear consent and aftercare. If you have a bleeding disorder, use anticoagulants, or have an active infection (BV, thrush, UTI) or unexplained bleeding, you’ll need tailored advice or deferral.
Combining with other approaches. PRP does not replace pelvic floor physiotherapy if protective guarding keeps the entrance tight after painful experiences; in that scenario, down-training and graded dilator work restore comfort more effectively. Nor does it treat infections; suspected BV/thrush/UTIs need assessment and targeted care. In practice, the most comfortable outcomes come from the right order, precise product placement (if the vestibule is the sore spot, fingertip-apply local oestrogen there), and regular reviews to titrate to the lowest effective maintenance once comfortable.
For a plain-English overview of how treatments are sequenced in our pathway and practical planning such as session numbers and budgeting, see our notes on treatment prices.
Clinical Context
Who might consider PRP? Those with GSM whose main problem is entrance-focused burn or micro-tears despite a solid routine of moisturiser and compatible lubricant—especially if local oestrogen or DHEA is unsuitable or declined—or people who improved on local therapy but still have friction pain. Some explore PRP as an adjunct rather than a replacement.
Who should pause or avoid for now? Anyone with active BV/thrush/UTI, malodorous discharge, fever, severe pelvic pain, visible blood in urine, new post-menopausal bleeding, unhealed surgery, or poorly controlled bleeding risk. If your main barrier is pelvic floor guarding, start with pelvic health physiotherapy; injections cannot relax muscles.
Alternatives and next steps. Keep external care gentle (lukewarm water; bland emollient as a soap substitute), choose breathable underwear, and review irritants (perfumed washes/liners, tight sports kit, chlorine without rinsing). If symptoms persist, discuss targeted local oestrogen/DHEA placement and whether an adjunct such as PRP is justified. Plan review at 6–12 weeks to adjust towards the lowest effective maintenance. Educational only. Results vary. Not a cure.
Evidence-Based Approaches
Guideline first lines (UK): Patient-friendly NHS pages outline symptom basics and self-care for vaginal dryness. The NICE Menopause Guideline (NG23) recommends offering information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life; local options can be used with or without HRT.
Comparators with stronger evidence: Systematic reviews in the Cochrane Library show that local vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo across creams, tablets/pessaries and rings—providing the current benchmark for symptom relief.
PRP evidence (emerging): Peer-reviewed studies and overviews indexed on PubMed report small trials and case series of PRP in GSM and vestibular pain, suggesting potential benefit but noting heterogeneity in preparation, dosing and follow-up, and the need for larger, controlled trials before routine use.
Prescribing and product detail (for local therapies): UK product information and cautions for vaginal oestrogens and prasterone (DHEA) are listed in the British National Formulary (BNF). PRP kits/devices should meet UK medical-device standards and be used with documented consent and aftercare.
Applying the evidence: follow a stepped plan—foundations → local therapy if needed → consider PRP only as an adjunct when guideline-led measures are insufficient or unsuitable, with transparent discussion of benefits, limits, costs and maintenance, and with careful placement at the symptomatic entrance when relevant.